一项关于白消安、环磷酰胺和依托泊苷随后进行自体移植治疗缓解期急性髓系白血病的初步研究。 - Suppr | 超能文献

A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission.

作者信息

Bilgrami S, Edwards R L, Bona R D, Kazierad D, Furlong F, Fox J, Clive J, Naqvi B H, Tutschka P J

机构信息

Bone Marrow Transplant Program, University of Connecticut Health Center, Farmington, Conn 06030, USA.

出版信息

Acta Haematol. 2000;104(2-3):144-7. doi: 10.1159/000039751.

DOI:10.1159/000039751

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission.

Acta Haematol. 2000;104(2-3):144-7. doi: 10.1159/000039751.

2

Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.

Bone Marrow Transplant. 1996 Jul;18(1):9-14.

3

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

Bone Marrow Transplant. 2000 Oct;26(7):711-6. doi: 10.1038/sj.bmt.1702598.

4

Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.

Ann Hematol. 2002 Feb;81(2):96-102. doi: 10.1007/s00277-001-0413-8. Epub 2002 Jan 10.

5

High-dose chemotherapy and autologous stem cell rescue for acute myeloid leukemia remains a safe, effective, and valid option.

Transplant Proc. 2000 Nov;32(7):2464-6. doi: 10.1016/s0041-1345(00)01745-0.

6

High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

Clin Cancer Res. 1997 Dec;3(12 Pt 2):2671-5.

7

A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):377-83. doi: 10.1016/j.clml.2015.02.016. Epub 2015 Feb 14.

8

Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution.

J Clin Oncol. 1993 Sep;11(9):1661-7. doi: 10.1200/JCO.1993.11.9.1661.

9

Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1343-9. doi: 10.1016/j.bbmt.2006.08.039.

10

Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.

Bone Marrow Transplant. 2011 Jan;46(1):105-9. doi: 10.1038/bmt.2010.71. Epub 2010 Apr 12.

引用本文的文献

1

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Blood Cancer J. 2014 May 30;4(5):e216. doi: 10.1038/bcj.2014.35.